US FDA Regulatory Shift to Boost Philip Morris' Zyn Sales by Millions
PM sits 32% above its 52-week low of $142.11.
Summary
The U.S. FDA has adopted a new policy of 'enforcement discretion' for unauthorized vaping and nicotine pouch products, effectively loosening regulations. This significant shift could allow hundreds more products to enter the market. This change is a major positive for tobacco companies, with a Barclays analyst forecasting Philip Morris International could sell up to an additional 12 million Zyn nicotine pouches this year. This directly impacts PM's sales and market share in the smoke-free product category, reversing a prior trend of stricter FDA scrutiny.
At the time of this announcement, PM was trading at $187.76 on NYSE in the Trade & Services sector, with a market capitalization of approximately $294.6B. The 52-week trading range was $142.11 to $193.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.